Adaptive Biotechnologies Corp. (ADPT)

In the past six months, ADPT's stock has been impacted by strong financial results for Q1 2026, exceeding forecasts by approximately 16.4%, primarily driven by its Minimal Residual Disease (MRD) business. Adaptive Biotechnologies also raised its full-year 2026 MRD revenue guidance to between $260 million and $270 million. In February 2026, the company reported strong execution and progress in 2025, with 46% revenue growth and profitability in its MRD business. Insider trading activity has also been noted, with the Chief Operating Officer selling over 19,000 company shares in April 2026 as part of a Rule 10b5-1 trading plan. The stock price has shown volatility, moving 11% a week, but ADPT outperformed the US Life Sciences industry and the broader US market over the past year.

Adaptive Biotechnologies expects its MRD revenue to be weighted approximately 45% in the first half of the year and 55% in the second half, indicating a degree of demand seasonality for these services.

Adaptive Biotechnologies Corp. is a commercial-stage biotechnology company in the Medical sector, specifically the Biomed/Gene industry, with a sub-industry of Pharmaceutical Products. The company decodes the genetic information of T-cell and B-cell receptors to identify immune response signatures. Its major products and services include the immunoSEQ platform and the clonoSEQ Assay, a molecular MRD detection method. Adaptive also provides T-cell receptor discovery services and collaborates on personalized cancer therapeutics and has a strategic partnership with Microsoft.

Adaptive Biotechnologies is headquartered in Seattle, Washington, and maintains research and operations facilities in North America and Europe.

Adaptive Biotechnologies has maintained a generally positive brand reputation, particularly within the scientific and investment communities. The company has received a consensus rating of "Moderate Buy" from analysts. Its leadership in hematology-oncology MRD was showcased with new clonoSEQ data presented at the 2025 ASH Annual Meeting. Strategic partnerships, such as the ongoing collaboration with Microsoft for immune data analysis, also contribute positively to its reputation.

Adaptive Biotechnologies has a diverse ownership structure, with approximately 99.17% of the stock held by institutions as of May 2026. Major institutional shareholders include Viking Global Investors Lp, BlackRock, Inc., Vanguard Group Inc, Price T Rowe Associates Inc /md/, Westfield Capital Management Co Lp, Geode Capital Management, Llc, State Street Corp, Invesco Ltd., Lord, Abbett & Co. Llc, and Goldman Sachs Group Inc. Individual investors and insiders also hold shares, with insiders owning about 3.71% of the company's stock.